TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria::~* Meets DSM-IV criteria for Major Depressive Disorder~* 18 to 75 years of age and able to provide legal consent~* Referred to Stanford ECT service by treating physician for unilateral electroconvulsive therapy with inpatient hospitalization~* Competed process for consenting to the clinical use of ECT according to California State law~* Females of childbearing potential will be required to use a double-barrier method of contraception, which includes foam and either condom and diaphragm, IUD, and/or implant during study.\&#xA; Exclusion Criteria:- Treatment with ECT in the 6 months prior to screening~* Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening~* Use of alcohol or illegal drugs within seven days of randomization or during study. Patients may be excluded for use during a period greater than 7 days, per study physician's discretion~* Presence of unstable or untreated cardiovascular disease, hypertension, or endocrine disorder as determined by the investigator~* use of antipsychotic, antidepressant, or other prescription medications unless dose is stable for at least 7 days prior to randomization.~* Use of any investigational treatment within 30 days of randomization~* Previous allergic reaction to memantine or drugs of similar chemical structure.~* Women who are pregnant or breastfeeding are not advised to participate in the research study~* Any neurological disorder or organic brain condition that would confound neurocognitive testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Oral Capsule (Type: PLACEBO_COMPARATOR): Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
- memantine (Type: EXPERIMENTAL): Patients receive memantine starting the day before ECT begins and while receiving ECT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women who presented to a single urogynecologist's office for an initial consultation with a complaint of urinary incontinence and/or pelvic organ prolapse~Exclusion Criteria:~* Being a minor~* Pregnancy~* Allergy to Lidocaine or aqueous lubricant gel~* Any current use of analgesia~* Structural abnormalities of the urethra~* Active genital Herpes or other vulvovaginal infections or inability to cooperate with pain assessment due to mental disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): 2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
- Aqueous gel (Type: PLACEBO_COMPARATOR): Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* On statin treatment for at least 3 months (fluvastatin, simvastatin, pravastatin, rosuvastatin, or atorvastatin) for primary prevention of cardiovascular disease~* HIV Ribonucleic Acid (RNA) below 50 copies/mL, minimum duration 3 months~* On a stable (\> 3 months) ARV treatment including at least one of the following drugs: LPV/r, ATZ/r, DRV/r, or EFV~* No previous virological escape or virological escape documented with a genotype at the time of failure only showing a K103M mutation.~Exclusion Criteria:~* Probability of cardiovascular complications of \> 20% according to the Swiss GSLA (Groupe de travail Lipide et Athérosclérose/Swiss Atherosclerosis Association) guidelines~* Previous cardiovascular disease (including stroke)~* Known diabetes~* Known intolerance of ETR~* Presence of a documented drug mutation (excluding the K103M)~* Regimen including non-boosted ATZ~* Known hyperlipidemia before ARV initiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Etravirine switch (Type: EXPERIMENTAL): Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years old~* Diagnosed with hypertension~* Blood pressure greater than or equal to 140/90 mm Hg OR~* currently taking antihypertensive medication~Exclusion Criteria:~* Pregnancy~* Severe comorbid condition(s) with life expectancy less than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improved Strategies for Outpatient Opioid Detoxification

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for current opiate dependence disorder of at least six months duration, supported by urine toxicology OR COWS score \> or =6 OR Naloxone Challenge .~* Seeking treatment for opioid dependence.~* In otherwise good health based on complete medical history and physical examination~* Able to give written informed consent.~Exclusion Criteria:~* Methadone maintenance treatment or regular use of illicit methadone (\> 30 mg per week).~* Maintenance on, or regular use of buprenorphine or other long-acting narcotic agonists~* Active medical illness which might make participation hazardous, such as untreated hypertension, acute hepatitis with AST or ALT \> 3 times normal, AIDS, unstable diabetes.~* Severe psychiatric illness (psychotic disorder, major depression, suicide risk or 1 or more suicide attempts within the past year.)~* Physiologically dependent on alcohol or sedative-hypnotics~* History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone, clonidine, or clonazepam.~* Chronic pain requiring opioid analgesia or anticipated surgery necessitating opioid medications~* AIDS dementia or other chronic organic mental disorder~* Pregnancy, lactation, failure to use contraception~* History of accidental drug overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine (Type: ACTIVE_COMPARATOR): Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
- Oral naltrexone (Type: ACTIVE_COMPARATOR): The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient of any ethnic group~* Patient was at least 2-15 years old and suffered from mild to severe atopic dermatitis (Rajka/Langeland score of at least 3)~Exclusion Criteria:~* Patient had a genetic epidermal barrier defect such as Netherton's syndrome or generalised erythroderma~* Patient had a clinically significant skin infection on the affected (and to be treated) area

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment in Children With Phelan McDermid Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Known pathogenic deletions or mutations in SHANK3 gene diagnosed by array CGH and/or direct sequencing.~* Children between 2 and 12 years of age.~* Open epiphyses on bone age x ray~Exclusion Criteria:~* closed epiphyses;~* active or suspected neoplasia;~* intracranial hypertension;~* hepatic insufficiency;~* renal insufficiency;~* cardiomegaly/valvulopathy;~* history of allergy to growth hormone or any component of the formulation (mecasermin);~* history of extreme prematurity (\<1000 grams) with associated early neo-natal complications, e.g. intra-cerebral~* hemorrhage, prolonged hypoxia, prolonged hypoglycemia;~* patients with comorbid conditions who are deemed too medically compromised to tolerate the risk of experimental treatment with growth hormone.~* Patient with visual problems that preclude the use of VEP's

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Phelan-McDermid syndrome (Type: EXPERIMENTAL): Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).~* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.~* Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).~* Any condition possibly affecting drug absorption (eg, gastrectomy).~* A positive urine drug screen.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- PF-06372865 (65mg) (Type: EXPERIMENTAL): None
- PF-06372865 (15mg) (Type: EXPERIMENTAL): None
- Pregabalin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal woman, less than 85 years old.~* BMD T-score ≤-2.5 of spine or hip (femoral neck) or ≤-2.0 with previous fracture (within 5 years).~* Normal physical exam, vital signs, electrocardiogram (ECG), and medical history.~* Laboratory tests within the normal range, including serum calcium, Vitamin D, parathyroid hormone (PTH) (1-84), serum phosphorus, and alkaline phosphatase.~Exclusion Criteria:~* BMD T-score ≤-5.0 at the lumbar spine or hip.~* History of bone disorders (for example, Paget's disease) other than postmenopausal osteoporosis.~* Significantly impaired renal function.~* History of any cancer.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Abaloparatide Transdermal (50 mcg) (Type: EXPERIMENTAL): Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
- Abaloparatide Transdermal (100 mcg) (Type: EXPERIMENTAL): Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
- Abaloparatide Transdermal (150 mcg) (Type: EXPERIMENTAL): Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
- Abaloparatide Injection (80 mcg) (Type: ACTIVE_COMPARATOR): Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
- Abaloparatide Transdermal Placebo (0 mcg) (Type: PLACEBO_COMPARATOR): Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Balance Study of Apraglutide in Patients With SBS-IF and Colon-in-Continuity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent for this trial prior to any trial specific assessment.~* Male and female subjects with SBS-IF and CIC, receiving parenteral support (PS), secondary to surgical resection of the small intestine with \<200 cm from duodenojejunal flexure.~* Subject must require PS at least 2 days per week and be considered stable.~* No restorative surgery intended to change PS requirements in the trial period.~* Age ≥18 years at screening.~Exclusion Criteria:~* Pregnancy or lactation.~* Body mass index equal or higher than 30 kg/m2 at the time of screening.~* Major abdominal surgery in the last 6 months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apraglutide SC injections, once weekly (Type: EXPERIMENTAL): Peptide analogue of GLP-2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Normal, healthy males and females 16 to 40 years of age~* Outpatients who have moderate to severe post-operative pain (confirmed by a Visual Analog Scale-Pain Severity Rating \[VAS-PSR\] score of at least 50 mm on a 100 mm VAS PSR) following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction~* Use of only the following pre-operative medication(s)/anesthetic(s): topical benzocaine, a short acting parenteral (local) anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide~Exclusion Criteria:~* Pregnancy or breast-feeding~* Alcohol or substance abuse~* Any serious medical or psychiatric disorder~* History of stomach ulcers, stomach bleed, or other bleeding disorders~* Use of a prescription or over-the-counter (OTC) drug with which administration of ibuprofen or any other non-steroidal anti-inflammatory drug (NSAID); acetaminophen (APAP); or codeine or any other opioid is contraindicated (including: opioids, antipsychotics, antianxiety agents, or other central nervous system depressants \[including alcohol\])

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: ACTIVE_COMPARATOR): None
- Treatment C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a primary diagnosis of ADHD~* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements~Exclusion Criteria:~* Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms~* History of seizure during the last 2 years~* Subject has any specific cardiac condition or family history of significant cardiac condition~* Subject is pregnant or lactating

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SPD503 (Guanfacine HCl) (2 mg) (Type: EXPERIMENTAL): None
- SPD503 (3 mg) (Type: EXPERIMENTAL): None
- SPD503 (4 mg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥18 and ≤75 years of age~* Clinical diagnosis of type 2 diabetes~* Currently treated with metformin, a sulfonylurea, or combination metformin/sulfonylurea; stable dose for ≥3 months~* HbA1c of 7.0-9.0% inclusive~* If taking lipid lowering medications, stable dose for \>30 days~Exclusion Criteria:~* Taken oral or injected prednisone or cortisone medications in the previous 30 days. (Topical or inhaled steroids will not be considered excluded medications.)~* Current use of insulin or TZD's, or incretins~* LDL \<70 mg/dL~* Serum triglycerides \>500 mg/dL~* History of hypertriglyceridemia-induced pancreatitis~* History of gastrointestinal disorder such as dysphagia, swallowing disorder, intestinal motility disorder or prior bowel obstruction~* History or presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study~* Unable to follow the study protocol~* Unable to speak, read and write in English~* Pregnant, planning to become pregnant, breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Welchol then Placebo (Type: PLACEBO_COMPARATOR): 3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
- Placebo then Welchol (Type: PLACEBO_COMPARATOR): Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspiration of Residual Gastric Contents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* born at 32 weeks of less of gestational age~* birth weight \</= to 1250 grams~* receiving some enteral feedings by 72 hours of age~* receiving parenteral feedings by 24 hours of age~Exclusion Criteria:~* Congenital or chromosomal abnormalities~* complex congenital heart diseases and congenital anatomic gastrointestinal abnormalities

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- Routine aspiration of gastric contents (Type: ACTIVE_COMPARATOR): Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
- No aspiration of gastric contents (Type: EXPERIMENTAL): Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete